The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections
Open accessAbstract
SUMMARY: The acyclic nucleoside phosphonates HPMPC (cidofovir), PMEA (adefovir), and PMPA (tenofovir) have proved to be effective in vitro (cell culture systems) and in vivo (animal models and clinical studies) against a wide variety of DNA virus and retrovirus infections: cidofovir against herpesvirus (herpes simplex virus types 1 and 2 varicella-zoster virus, cytomegalovirus [CMV], Epstein-Barr virus, and human herpesviruses 6, 7, and 8), polyomavirus, papillomavirus, adenovirus, and poxvirus (variola virus, cowpox virus, vaccinia virus, molluscum contagiosum virus, and orf virus) infections; adefovir against herpesvirus, hepadnavirus (human hepatitis B virus), and retrovirus (human immunodeficiency virus types 1 [HIV-1] and 2 [HIV-2], simian immunodeficiency virus, and feline immunodeficiency virus) infections; and tenofovir against both hepadnavirus and retrovirus infections. Cidofovir (Vistide) has been officially approved for the treatment of CMV retinitis in AIDS patients, tenofovir disoproxil fumarate (Viread) has been approved for the treatment of HIV infections (i.e., AIDS), and adefovir dipivoxil (Hepsera) has been approved for the treatment of chronic hepatitis B. Nephrotoxicity is the dose-limiting side effect for cidofovir (Vistide) when used intravenously (5 mg/kg); no toxic side effects have been described for adefovir dipivoxil and tenofovir disoproxil fumarate, at the approved doses (Hepsera at 10 mg orally daily and Viread at 300 mg orally daily).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenine
Tsai, C.-C., Follis, K. E., Sabo, A., Beck, T. W., Grant, R. F., Bischofberger, N., Benveniste, R. E., & Black, R. (1995) · Science · doi:10.1126/science.270.5239.1197 · Cited by 563
Birkus, G., Hitchcock, M. J. M., & Cihlar, T. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.716-723.2002 · Cited by 441
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase
Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., & Johnson, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106743200 · Cited by 403
Lalezari, J. P., Stagg, R. J., Kuppermann, B. D., Holland, G. N., Kramer, F., Ives, D. V., Youle, M., Robinson, M. R., Drew, W. L., & Jaffe, H. S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00001 · Cited by 372
Cihlar, T., Lin, D. C., Pritchard, J. B., Fuller, M. D., Mendel, D. B., & Sweet, D. H. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23084-4 · Cited by 345
Kedes, D. H., & Ganem, D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119380 · Cited by 316
Clinical Pharmacokinetics of the Antiviral Nucleotide Analogues Cidofovir and Adefovir
Cundy, K. C. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936020-00004 · Cited by 303
Cidofovir in the treatment of poxvirus infections
De Clercq, E. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00008-6 · Cited by 283
Self-citationVernazza, P. L., Troiani, L., Flepp, M. J., Cone, R. W., Schock, J., Roth, F., Boggian, K., Cohen, M. S., Fiscus, S. A., & Eron, J. J. (2000) · AIDS · doi:10.1097/00002030-200001280-00006 · Cited by 271
Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D., Chen, S.-S., Miller, M. D., Isaacson, E., & Cheng, A. K. (2002) · AIDS · doi:10.1097/00002030-200206140-00008 · Cited by 270
Naesens, L., Snoeck, R., Andrei, G., Balzarini, J., Neyts, J., & De Clercq, E. (1997) · Antiviral Chemistry and Chemotherapy · doi:10.1177/095632029700800101 · Cited by 243
Self-citationOtten, R. A., Smith, D. K., Adams, D. R., Pullium, J. K., Jackson, E., Kim, C. N., Jaffe, H., Janssen, R., Butera, S., & Folks, T. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9771-9775.2000 · Cited by 239
Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I., & Holy, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.12.1839 · Cited by 223
Self-citationCidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
Ljungman, P. (2001) · Blood · doi:10.1182/blood.v97.2.388 · Cited by 220
Cidofovir Protects Mice against Lethal Aerosol or Intranasal Cowpox Virus Challenge
Bray, M., Martinez, M., Smee, D. F., Kefauver, D., Thompson, E., & Huggins, J. W. (2000) · The Journal of Infectious Diseases · doi:10.1086/315190 · Cited by 216
Kahn, J. (1999) · JAMA · doi:10.1001/jama.282.24.2305 · Cited by 199
(1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-4-199702150-00002 · Cited by 178
Antiviral agents active against human herpesviruses HHV‐6, HHV‐7 and HHV‐8
De Clercq, E., Naesens, L., De Bolle, L., Schols, D., Zhang, Y., & Neyts, J. (2001) · Reviews in Medical Virology · doi:10.1002/rmv.336 · Cited by 175
Self-citationChen, Y., Scieux, C., Garrait, V., Socié, G., Rocha, V., Molina, J., Thouvenot, D., Morfin, F., Hocqueloux, L., Garderet, L., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/314052 · Cited by 165
Deeks, S. G., Barditch-Crovo, P., Lietman, P. S., Hwang, F., Cundy, K. C., Rooney, J. F., Hellmann, N. S., Safrin, S., & Kahn, J. O. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2380 · Cited by 158
Margot, N., Isaacson, E., McGowan, I., Cheng, A., Schooley, R. T., & Miller, M. D. (2002) · AIDS · doi:10.1097/00002030-200206140-00004 · Cited by 146
Smee, D. F., Sidwell, R. W., Kefauver, D., Bray, M., & Huggins, J. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1329-1335.2002 · Cited by 139
Lacy, S. A., Hitchcock, M. J. M., Lee, W. A., Tellier, P., & Cundy, K. C. (1998) · Toxicological Sciences · doi:10.1093/toxsci/44.2.97 · Cited by 136
Abdulkarim, B., Sabri, S., Deutsch, É., Chagraoui, H., Maggiorella, L., Thierry, J., Eschwège, F., Vainchenker, W., Chouaı̈b, S., & Bourhis, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205006 · Cited by 130
Cihlář, T., Birkuš, G., Greenwalt, D. E., & Hitchcock, M. J. M. (2002) · Antiviral Research · doi:10.1016/s0166-3542(01)00210-8 · Cited by 123
Hillenkamp, J., Reinhard, T., Ross, R. S., Böhringer, D., Cartsburg, O., Roggendorf, M., Clercq, E. D., Godehardt, E. A. J., & Sundmacher, R. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)00992-2 · Cited by 122
Rompay, K. K. A. V., McChesney, M. B., Aguirre, N. L., Schmidt, K. A., Bischofberger, N., & Marthas, M. L. (2001) · The Journal of Infectious Diseases · doi:10.1086/322781 · Cited by 121
Lalezari, J. P., Holland, G. N., Kramer, F., McKinley, G. F., Kemper, C. A., Ives, D. V., Nelson, R. P., Hardy, W. D., Kuppermann, B. D., Northfelt, D., et al. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199804010-00008 · Cited by 113
Taoufik, Y., Gasnault, J., Karaterki, A., Férey, M.-P., Marchadier, E., Goujard, C., Lannuzel, A., Delfraissy, J. F., & Dussaix, É. (1998) · The Journal of Infectious Diseases · doi:10.1086/314496 · Cited by 109
Neyts, J. H., & Clercq, E. D. (1993) · Journal of Medical Virology · doi:10.1002/jmv.1890410312 · Cited by 108
Rompay, K. K. A. V., Cherrington, J. M., Marthas, M. L., Berardi, C. J., Mulato, A. S., Spinner, A., Tarara, R. P., Canfield, D. R., Telm, S., Bischofberger, N., et al. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2586 · Cited by 108
Barditch‐Crovo, P., Toole, J. J., Hendrix, C. W., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514057 · Cited by 99
Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6
Reymen, D., Naesens, L. M. J., Balzarini, J. M., Holý, A., Dvořáková, H., & Clercq, E. D. (1995) · Antiviral Research · doi:10.1016/0166-3542(95)00058-5 · Cited by 96
Delmas, J., Schorr, O., Jamard, C., Gibbs, C. S., TREPO, C. G., Hantz, O., & Zoulim, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.425-433.2002 · Cited by 96
Fisher, E. J., Chaloner, K. M., Cohn, D. L., Grant, L. B., Alston, B., Brosgart, C. L., Schmetter, B., El-Sadr, W. M., & Sampson, J. H. (2001) · AIDS · doi:10.1097/00002030-200109070-00013 · Cited by 95
Kirsch, L. S., Arévalo, J. F., Clercq, E. D., de la Paz, E. C., Munguia, D., Garcia, R., & Freeman, W. R. (1995) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)71233-4 · Cited by 94
Naeger, L. K., Margot, N., & Miller, M. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2179-2184.2002 · Cited by 93
Cihlář, T., Fuller, M. D., Mulato, A. S., et al. (1998) · Virology · doi:10.1006/viro.1998.9299 · Cited by 92
Naeger, L. K., Margot, N., & Miller, M. D. (2001) · Antiviral Therapy · doi:10.1177/135965350100600205 · Cited by 92
Andreï, G., Snoeck, R., Piette, J. G., Delvenne, P., & Clercq, E. D. (1998) · PubMed · Cited by 89
Tarantal, A. F., Castillo, A. B., Ekert, J. E., Bischofberger, N., & Martin, R. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200203010-00001 · Cited by 87
Louie, M. J., Hogan, C., Hurley, A., Simon, V. R., Chung, C., Padte, N. N., Lamy, P. D., Flaherty, J. F., Coakley, D. F., Mascio, M. D., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00006 · Cited by 83
Luca, A. D., Giancola, M. L., Ammassari, A., Grisetti, S., Cingolani, A., Paglia, M. G., Govoni, A., Murri, R., Testa, L., Monforte, A. D., et al. (2000) · AIDS · doi:10.1097/00002030-200009290-00001 · Cited by 81
Deeks, S. G., Collier, A. C., Lalezari, J. P., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514150 · Cited by 80
Clercq, E. D. (1995) · Reviews in Medical Virology · doi:10.1002/rmv.1980050305 · Cited by 69
Tsai, C., Follis, K. E., Beck, T. W., Sabó, A., Bischofberger, N., & Dailey, P. J. (1997) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1997.13.707 · Cited by 67
Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir
Bray, M., Martinez, M., Kefauver, D. F., West, M. W., & Roy, C. J. (2002) · Antiviral Research · doi:10.1016/s0166-3542(01)00220-0 · Cited by 67
Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
Smee, D. F., Bailey, K. M., WONG, M., & Sidwell, R. W. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00105-4 · Cited by 65
The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (2000) · AIDS · doi:10.1097/00002030-200007280-00013 · Cited by 64
Cherrington, J. M., Mulato, A. S., Fuller, M. D., & Chen, M. S. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.2212 · Cited by 60
Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin
Kesson, A. M., Ferguson, J., Rawlinson, W. D., & Cunningham, A. L. (1997) · Clinical Infectious Diseases · doi:10.1086/515534 · Cited by 58
BANKER, A. S., Arévalo, J. F., Munguia, D., Rahhal, F. M., Ishimoto, B. M., Berry, C. C., Clercq, E. D., Ochabski, R., Taşkintuna, İ., & Freeman, W. R. (1997) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70781-0 · Cited by 47
Palmer, S., Margot, N., Gilbert, H., Shaw, N., Buckheit, R. W., & Miller, M. D. (2001) · AIDS Research and Human Retroviruses · doi:10.1089/088922201316912772 · Cited by 46
Cihlář, T., & Chen, M. (1997) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029700800302 · Cited by 44
Parapoxviruses are strongly inhibited in vitro by cidofovir
Nettleton, P. F., Gilray, J. A., Reid, H. W., et al. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00130-3 · Cited by 42
Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*
Birkuš, G., Hájek, M., Kramata, P., Votruba, I., Holý, A., & Otová, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1610-1613.2002 · Cited by 42
Harrigan, P. R., Miller, M. D., McKenna, P., Brumme, Z. L., & Larder, B. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1067-1072.2002 · Cited by 42
Fol, A., Sogocio, K. M., Anderson, B. D., Kavlick, M. F., Saville, M. W., Wainberg, M. A., Gu, Z., Cherrington, J. M., Mitsuya, H., & Yarchoan, R. (1996) · Antiviral Research · doi:10.1016/0166-3542(95)00985-x · Cited by 41
Kopp, T., Geusau, A., Rieger, A., & Stingl, G. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04747.x · Cited by 40
Selective Activity of Various Nucleoside and Nucleotide Analogues against Human Herpesvirus 6 and 7
TAKAHASHI, K., Suzuki, M., Iwata, Y., Shigeta, S., Yamanishi, K., & Clercq, E. D. (1997) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029700800102 · Cited by 39
Romanowski, E. G., Yates, K. A., & Gordon, Y. J. (2001) · Antiviral Research · doi:10.1016/s0166-3542(01)00166-8 · Cited by 38
Cullen, J. M., Li, D. H., Brown, C. L., Eisenberg, E. J., Cundy, K. C., Wolfe, J., Toole, J. J., & Gibbs, C. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2740-2745.2001 · Cited by 38
Ganciclovir and Cidofovir Treatment of Cytomegalovirus-Induced Myocarditis in Mice
Lenzo, J. C., SHELLAM, G. R., & LAWSON, C. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1444-1449.2001 · Cited by 33
Smith, M. S., Foresman, L. L., Lopez, G. J., Tsay, J., Wodarz, D., Lifson, J. D., Page, A., Wang, C., Li, Z., Adany, I., et al. (2000) · Virology · doi:10.1006/viro.2000.0609 · Cited by 31
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Self-citationAcyclic nucleoside phosphonates: a key class of antiviral drugs
Clercq, E. D., & Holý, A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1877 · Cited by 688
Antiviral Drug Resistance of Human Cytomegalovirus
Lurain, N. S., & Chou, S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00009-10 · Cited by 596
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy
De Bolle, L., Naesens, L., & De Clercq, E. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.217-245.2005 · Cited by 529
Self-citation
Metadata
- Authors
- De Clercq, E.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2003-10
- Volume
- 16
- Issue
- 4
- Pages
- 569-596
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2168652503
- Cited by
- 369
- References
- 66
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.